Navigation Links
InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
Date:2/1/2010

n. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon these data, in combination with the other efficacy analyses and safety results the company has submitted in support of its NDA filing and currently intends to submit in support of its MAA filing. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail in the risk factors attached as Exhibit 99.3 to InterMune’s Form 8-K filed with the SEC on January 20, 2010, and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 8-K and InterMune's other periodic reports filed with the SEC.  InterMune undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in InterMune's expectations.  

SOURCE InterMune, Inc.

RELATED LINKS

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , Germany , and ... , Exclusive global license from ... SF3B1 mutations, including next-generation sequencing (NGS) gene panels, for ... be targeted by new test, indicate favorable prognosis for ... QIAGEN sees potential for developing companion diagnostics ...
(Date:7/24/2014)... CITY, Calif., July 24, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis systems, today reported financial results for ... First quarter overview: , Revenues of $47.5 ... , Diluted EPS of $0.21, up 50% over last ... Medical market revenues of $7.2 million, up 20% over ...
(Date:7/24/2014)... MOUNTAIN VIEW, Calif. , July 24, 2014 /PRNewswire/ ... that it will release its second quarter 2014 financial ... 31, 2014. In conjunction with the release, the ... community at 5:00 p.m. Eastern Time on ... results of the quarter and other business developments. ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... Heska Corporation (Nasdaq: HSKA ; "Heska" or ... quarter ended September 30, 2009. , (Logo: ... the most profitable quarter this year and the financial ... flow from our operations has allowed us to reduce ...
... Lumenis Ltd., a global developer, manufacturer and seller of ... ophthalmic applications, announced that on September 30th, 2009 the ... PolyScope Flexible Endoscope can now be sold in the ... indicated in flexible endoscopic procedures for diagnostic and therapeutic ...
Cached Medicine Technology:Heska Announces Q309 Results 2Heska Announces Q309 Results 3Heska Announces Q309 Results 4Heska Announces Q309 Results 5Lumenis Receives 510K Clearance for the PolyScope Disposable Flexible Endoscope 2Lumenis Receives 510K Clearance for the PolyScope Disposable Flexible Endoscope 3Lumenis Receives 510K Clearance for the PolyScope Disposable Flexible Endoscope 4
(Date:7/26/2014)... July 26, 2014 The birth control ... Mirena IUD contraceptive of new legal information on the ... showing the number of lawsuits pending for July alleging ... free resource for those using popular prescription drugs and ... recalls, studies and legal news all in one place, ...
(Date:7/25/2014)... In recent years, men have become more ... the symptoms associated with age-related testosterone decline. Amid concerns about ... new case study from Renew Man helps to ... using bioidentical hormones. , The case study centers around ... found himself beginning to feel the effects of age-related hormonal ...
(Date:7/25/2014)... As reported by the New Orleans Advocate in ... (7/3), the state of Louisiana has recently seen a large ... cocaine. Officials believe the increase is due to a misconception ... marijuana. However, both doctors and police confirm that that belief ... call it “poison,” doctors have acknowledged that the Louisiana Poison ...
(Date:7/25/2014)... Sport Court® provided and ... Nike National Invitational Tournament (NIT) in Chicago at ... National Tournament (USJN) in Washington D.C. at the ... these prestigious national tournaments included 44 Sport Court Maple ... playing surface at McCormick Place for the NIT, and ...
(Date:7/25/2014)... TX (PRWEB) July 25, 2014 The ... Family Fun Fest on Sunday, July 27 at Discovery ... franchises include Memorial, Copperfield, Katy, Pearland, Friendswood, Spring, The ... in The Heights. , “We’re thrilled to be ... year,” said Heather Belcher who owns the Sugarland-Missouri City ...
Breaking Medicine News(10 mins):Health News:DrugNews Adds Latest Court Updates on Mirena IUD Lawsuits 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2
... Several years ago, scientists at Beth Israel Deaconess Medical ... regarding the Akt molecular pathway, a popular target for ... protein Akt1 was actively preventing cancer cells ... was actually promoting breast cancer cell migration. And, ...
... be one of the leading causes of oral cancer, ... experimental animals has traditionally been limited to examining the ... rather than on observing the effects of carcinogens that ... completed study conducted collaboratively by Dr. Joseph Guttenplan, a ...
... for building new organs to replace damaged livers, blood vessels ... cells grown in a lab dish to form 3-D shapes ... of Health Sciences and Technology (HST) have come up with ... cells in cubes and arranging them into 3-D structures, just ...
... strong, healthy bones. But new research from North Carolina ... the earliest days of life could have a more ... obesity than previously thought. During an 18-day trial ... levels of bone density and strength in 12 piglets ...
... physical competition, not attraction, was central in winning ... State anthropologist., "There is sexual competition in many ... professor of biological anthropology. Many researchers have ... sexual selection. They thought that people,s mating success ...
... ... (NWS), a leading provider of water conservation and water management services, was recently awarded ... ... 2010 -- National Water Services, Inc. (NWS), a leading provider of ...
Cached Medicine News:Health News:Study identifies 1 of the mechanisms behind breast cancer metastasis 2Health News:NYU College of Dentistry, Penn State develop new model for investigating tobacco/oral cancer link 2Health News:Tissue engineers create a new way to assemble artificial tissues 2Health News:Tissue engineers create a new way to assemble artificial tissues 3Health News:Calcium in early life may prevent obesity later 2Health News:It was brawn over beauty in human mating competition 2Health News:National Water Services, Inc. Receives WBE Certification 2
PDA format of the well-known standard antimicrobial reference....
PDA application providing a complete guide for the diagnosis and management of electrolyte disorders....
Contains the most common procedures from all orthopedic sub-specialties organized by body area....
Consists of the print and PDA versions of Harrison's Manual of Medicine 15th Edition. Provides high-end medical content via PDA....
Medicine Products: